Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Sponsor: Akeso
Summary
The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.
Official title: A Randomized, Double-blind, Phase III Clinical Study on the Efficacy and Safety of AK104 Versus Placebo as Adjuvant Therapy for Hepatocellular Carcinoma With High Risk of Recurrence After Curative Resection
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
570
Start Date
2023-01-05
Completion Date
2027-01-01
Last Updated
2025-03-12
Healthy Volunteers
No
Conditions
Interventions
AK104
Subjects will receive AK104 until disease progression or for a maximum of 16 cycles
placebo
Subjects will receive placebo until disease progression or for a maximum of 16 cycles
Locations (1)
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China